Oscar: An Overlooked 2026 Inflection

Yiannis Zourmpanos13.85K FollowersFollow5ShareSavePlay(10min)CommentsSummaryOscar Health is delivering A-grade growth with ~37% YoY revenue expansion and roughly 30% forward topline growth visibility.Management plans a disciplined ~28% weighted average rate increase in 2026 to directly address margins and profitability.Shares remain largely flat since prior coverage, creating a mispricing despite improving fundamentals and clearer strategic execution.The House-passed ACA subsidy extension temporarily reduces downside risk, even as long-term Senate approval remains uncertain.AI-driven cost controls and targeted products position Oscar for a potential profitability inflection and EPS surprise in 2026. Khanchit Khirisutchalual/iStock via Getty Images Investment Thesis Oscar Health, Inc. (OSCR) stock's upside sharpens as policy risk eases and fundamentals align. With ~30% forward topline growth, OSCR pairs scale with discipline via a planned 28% 2026 rate reset aimed squarely at profitability.This article was written byYiannis Zourmpanos13.85K FollowersFollowHi, I'm Yiannis. Spotting winners before they break out is what I do best.Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certified Accountant, Fellow Member of ACCA Global, with BSc and MSc degrees from U.K. business schools. Investment Style: Spotting high-potential winners before they break out, focusing on asymmetric opportunities (with at least upside potential of 3-5X outweighing the downside risk). By leveraging market inefficiencies and contrarian insights, we seek to maximize long-term compounding while protecting against capital impairment.Risk management is paramount—we seek a strong margin of safety to protect against capital impairment while maximizing long-term compounding. Our 2-3 year investment horizon allows us to ride out volatility, ensuring that patience, discipline, and intelligent capital allocation drive outsized returns over time.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.